Sensyne Health
-
Revenue quadruples in Sensyne Health trading update for 2021
The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.
-
Sensyne Health licenses MagnifEye technology to Excalibur Healthcare
Excalibur will integrate MagnifEye into its lateral flow products for global marketing to customers in both the public and private sectors.
-
Sensyne Health has launched AI algorithm for real-time patient management
Co-developed with Chelsea and Westminster Hospital, this is the first in a series of operational AI algorithms to be launched commercially and offered across the UK and US health systems.
-
Sensyne Health launches diabetes monitoring product in US
The solution will be offered to US health systems and health plans through Cognizant, their US sales and marketing partner.